New
HealthMore in Health→
Vera's Trutakna Delivers Strong Final Phase 3 Results in IgA Nephropathy
Key Takeaways
- Vera reported strong final Phase 3 results for its kidney drug Trutakna in IgA nephropathy.
- The drug stabilized kidney function in IgAN patients, according to the report.
- Trutakna also reduced the risk of death and other complications associated with the disease.
- The final readout positions the therapy at the last stage before a potential regulatory filing.
DE
DT Editorial Team··via statnews.com